Back to search results

Surgical Treatment for Pancreatic Cancer with Limited Spread

This study is looking at a surgical treatment for pancreatic cancer that has spread to a few spots in the liver or lungs (oligometastatic pancreatic ductal adenocarcinoma). You can join if you have this type of cancer and haven't started treatment yet. Everyone in the study will receive a chemotherapy called NALIRIFOX before surgery. If your cancer gets worse after the first four cycles of NALIRIFOX, you will leave the study. If your cancer stays the same or shrinks, doctors will check if the main tumor can be removed. If it can, you will have surgery to remove the main tumor and the spots in your liver or lungs. The study will measure how successful the surgery is at removing all visible cancer (R0/R1 resection) within 4-12 weeks after surgery. The current status of this study is unclear.

Study design
This is a single-arm study, meaning everyone receives the same treatment, and there is no comparison group. It plans to enroll 40 participants.
What's involved
You will receive NALIRIFOX chemotherapy. If your cancer responds well, you will undergo exploratory surgery and potentially have the primary tumor and metastases removed.
Compensation
Not stated in the trial record.
Follow-up
The main goal of the study is measured between prior to surgery and 4-12 weeks after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07340151

Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

Recruiting
NAAll AgesInterventional
The University of Texas Health Science Center at San Antonio
~40 participants
Updated 2026-04-14 on ClinicalTrials.gov
What's tested:Surgical resection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy of R0/R1 resection
Measured over Prior to surgery to 4-12 weeks after surgery

Conditions

Adenocarcinoma of the Pancreas

Explore related trials

Pancreatic Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Lei Zheng, MD, PhD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center at San Antonio

Who to contact

Lei Zheng, MD, PhD
[email protected]
(210) 450-1406
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Definition of limited hepatic metastasis: 1 to 5 metastases in CT/MRI, which are potentially resectable or treatable by ablative procedures.
Note 1: Patients also fulfil this inclusion criterion if a hepatic metastasis was partly or entirely removed as part of the diagnosis and is thus not detectable by CT/MRI scan at screening.
Note 2: If more than 5 metastases are unexpectedly detected during surgery, it is not a violation of this inclusion criterion if the excess metastases had not been detectable by CT/MRI scan at screening.
Definition of limited pulmonary metastasis: 1 to 4 pulmonary nodules seen on CT/MRI, suspicious for pulmonary metastases as per the multidisciplinary tumor board radiologist and surgeon. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 4. Patients ≥18 years at the time of signing the informed consent 5. Being a candidate for chemotherapy with NALIRIFOX 6. Patient's written informed consent prior to any trial-specific procedure 7. Patient's legal capacity to consent to participation in the clinical trial.

What this trial measures

  • Efficacy of R0/R1 resectionPrior to surgery to 4-12 weeks after surgery

    Assessed by tumor imaging